Otamixaban (XRP0673)

DRUG3 trials

Sponsors

Sanofi

Conditions

Angioplasty, Transluminal, Percutaneous CoronaryCoronary DiseaseRenal Impairment

Phase 1

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

CompletedNCT01120314

SanofiRenal Impairment

Start: 2010-04-30End: 2011-07-31Updated: 2014-05-12

Phase 2

The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention

CompletedNCT00133731

SanofiAngioplasty, Transluminal, Percutaneous Coronary

Start: 2004-09-30End: 2005-10-31Updated: 2008-07-02

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

CompletedNCT00317395

SanofiCoronary Disease

Start: 2006-06-30End: 2009-03-31Updated: 2014-12-03

Related Papers

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.

2009-08-2878 citations